Astellas Pharma
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Astellas Pharma sits in the top decile of US sponsors by registered trial count (#179 of 15,742 sponsors by registered trial count).
Astellas Pharma: 165 sponsored US clinical trials, 2 recruiting.
Astellas Pharma sponsors 165 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 143 completed. 47 of these trials are in Phase 3-4 (later-stage) and 113 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Candidemia, with 4 trials.
Top-decile sponsor footprint
Astellas Pharma ranks in the top decile of sponsors by registered trial count (#179 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
143 of 162 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
165 total, page 1 of 4
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
NCT07094204
A Study of ASP3082 in Adults With Advanced Solid Tumors
NCT05382559
A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors
NCT06364696
A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery
NCT05457842
A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy
NCT04641962
A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD)
NCT04184882
A Study for Ureter Visualization, Using ASP5354 in Subjects Undergoing Laparoscopic/Minimally Invasive Colorectal Surgery
NCT04238481
Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury (AKI) Following Coronary Artery Bypass Graft (CABG) and/or Valve Surgery
NCT03941483
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
NCT03219333
An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors
NCT02038673
A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate
NCT01554696
A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8%Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)
NCT01533428
Drug Interaction Study of Isavuconazole and Tacrolimus
NCT01535547
A Study to Evaluate the Effect of ASP8597 in Adult Kidney Transplant Patients
NCT01442337
Drug Interaction Study of Isavuconazole and Cyclosporine
NCT01494597
A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100
NCT01534052
A Single Oral Dose Study to Compare the Bioavailability Between Two Different Tablet Formulations and Assess if There is a Food Effect With the New Formulation
NCT01484964
A Single Oral Dose Study of ASP015K in Healthy Volunteers Assessing the Relative Bioavailability Across Three Tablet Strengths From a New Formulation of ASP015K
NCT01486017
A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical Prostatectomy
NCT01371994
A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4
NCT01409135
A Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease (AD) Taking a Stable Dose of Donepezil
NCT01406145
Drug Interaction Study of Isavuconazole and Midazolam
NCT01406171
A Study in Healthy Volunteers Comparing Two Different Liquid Formulations of Solifenacin With Each Other and With the Tablet Formulation
NCT01406158
A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)
NCT01334918
Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene
NCT01221077
A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer
NCT01288911
Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
NCT01186861
A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept
NCT01339481
A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
NCT01101906
Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)
NCT01284192
A Study to Assess Pharmacokinetic, Pharmacodynamic, Safety and Tolerability of ASKP1240 in de Novo Kidney Transplantation
NCT01279538
A Study to Assess Intraocular Pressure and Ocular Safety of the Beta-3 Agonist Mirabegron in Research Subjects
NCT01284309
A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer
NCT01228760
A Study of the Effect of ASP1941 on Cardiac Repolarization in Healthy Subjects
NCT01232413
A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney Cancer
NCT01114230
A Study to Evaluate the Drug Interaction of ASP015K and Tacrolimus
NCT01190670
A Pilot Trial in a Sleep Laboratory Setting to Observe Night Time Bladder Function of Subjects With Overactive Bladder (OAB)
NCT01099345
A Study to Assess Drug Interaction of ASP015K and Midazolam
NCT01182077
A Study to Evaluate the Effect of Oral Mirabegron on the Heart in Healthy Males and Females
NCT01199523
A Study to Assess the Effect of Hepatic Function on the Pharmacokinetics and Safety of ASP1941
NCT01187186
A Study to Evaluate the Effect of ASP1941 in Combination With Metformin in Adult Patients With Type 2 Diabetes Mellitus
NCT01117584
A Study to Assess the Systemic Disposition of ASP1585 After Administration of 14C-labeled Drug
NCT01124747
A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis
NCT01096862
A Study to Evaluate the Effect of ASP1941 in Adult Patients With Type 2 Diabetes Mellitus
NCT01071850
A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Sitagliptin When Given Together to Healthy Subjects
NCT01104532
A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Methotrexate in Patients With Rheumatoid Arthritis
NCT01754805
Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.
NCT01093534
A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma
NCT00924989
A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
NCT01038804
A Study to Assess the Pharmacokinetics of ASP015K in Healthy Male Subjects
NCT01406132
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 59 |
| Phase 2 | 54 |
| Phase 3 | 28 |
| Phase 4 | 19 |
Therapeutic Areas
What is open in the Astellas Pharma pipeline
2 recruiting of 165 indexed (1% open); 143 completed (87%).
Phase mix: 47 late (III/IV) vs 113 early (I/II) (early-phase heavy).
Top condition: Candidemia (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Astellas Pharma: open-pipeline peers nationwide
Peers matched on 165 registered trials and 1% open enrollment, not the therapeutic-area sidebar.
Astellas Pharma sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 165 trials (± recruiting share)
- Teva Branded Pharmaceutical Products R&D · 167 trials · 4% recruiting
- Wyeth is now a wholly owned subsidiary of Pfizer · 167 trials · 0% recruiting
- Temple University · 163 trials · 13% recruiting
- Tufts University · 163 trials · 6% recruiting
Sponsors near 1% open enrollment (± trial volume)
- University of New Mexico · 1% recruiting · 168 trials
- Abbott Nutrition · 1% recruiting · 89 trials
- Baxalta now part of Shire · 1% recruiting · 74 trials
- Power Life Sciences · 2% recruiting · 62 trials
Related
What to do with this Astellas Pharma page
165 registered trials is a research-attention snapshot, not an endorsement of Astellas Pharma or any single study.
- 2 of Astellas Pharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Candidemia is the condition Astellas Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Candidemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Astellas Pharma pipeline card: 165 registered trials from official public datasets.Report a data error.